Medical therapy for obesity--current status and future hopes

George A Bray1

  • 1Pennington Center, 6400 Perkins Road, Baton Rouge, LA 70808, USA. brayga@pbrc.edu

Insights

New obesity drugs require excellent safety profiles for widespread use. Treatment focuses on managing this chronic disease by reducing food intake or increasing energy expenditure for sustained weight loss.

Area of Science:

  • Pharmacology and Therapeutics
  • Metabolic Diseases
  • Public Health

Background:

  • Obesity is a complex, chronic disease with diverse etiologies.
  • Effective treatment requires balancing individual risks of obesity against potential treatment side effects.
  • Current therapeutic strategies aim for disease management rather than a cure.

Purpose of the Study:

  • To outline the essential safety and efficacy criteria for novel obesity pharmacotherapies.
  • To emphasize the need for treatments that support long-term weight management.
  • To define the fundamental physiological outcomes required for successful obesity interventions.

Main Methods:

  • Review of established principles in pharmacotherapy selection for chronic conditions.
  • Analysis of risk-benefit assessments in the context of obesity management.
  • Evaluation of physiological targets for weight reduction.

Main Results:

  • Safety is paramount for broad patient acceptance of obesity medications.
  • Treatment efficacy is measured by the ability to achieve and maintain weight loss.
  • The net effect of any intervention must be reduced caloric intake or increased energy expenditure.

Conclusions:

  • Novel obesity drugs must demonstrate a highly favorable safety profile.
  • Successful obesity treatment necessitates a focus on sustained weight management.
  • Pharmacological interventions should aim to modulate energy balance through diet or expenditure.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...